植物医生IPO冲刺A股主板，高山植物护肤赛道跑出“单店之王”

Core Viewpoint - The domestic high-altitude plant skincare brand, Plant Doctor, is advancing its IPO process, with its prospectus disclosed on January 12, 2026, aiming to list on the main board of the Shenzhen Stock Exchange. If successful, it will become a rare enterprise in the A-share skincare sector focused on a "single brand specialty store" model [1]. Group 1: Business Strategy and Market Position - Plant Doctor has maintained a focus on a single brand for over 30 years, emphasizing "high-altitude plants, pure skin beauty," which has been validated by financial and market indicators [3]. - As of June 2025, Plant Doctor has over 4,200 offline stores and ranks first among single-brand cosmetics stores in China based on the 2024 all-channel retail sales [3]. - The brand has been recognized by Euromonitor as a "global leader in single-brand skincare specialty stores" for three consecutive years (2023-2025), providing third-party endorsement for its global positioning [3]. Group 2: Research and Development - Unlike many brands that rely on outsourcing and marketing, Plant Doctor emphasizes R&D investment, establishing a core competitive barrier through long-term collaboration with the Kunming Institute of Botany, Chinese Academy of Sciences [5]. - The joint R&D center serves as an innovation engine, with notable achievements such as the "key technology research and industrial application of Dendrobium active extract," which transformed large-molecule Dendrobium polysaccharides into more active Dendrobium oligosaccharides, winning a national commercial science and technology progress award [5]. - The brand has a research structure comprising "one center and five bases" across various locations, along with 223 patents, supporting its technological attributes and differentiated positioning [5]. Group 3: Business Model and Global Expansion - Plant Doctor's business model features a clear "dual-drive" characteristic, with over 4,000 offline stores serving as both sales channels and experience centers to enhance user engagement [7]. - The brand has initiated a global expansion strategy, with its store network extending beyond mainland China to markets such as Japan, Indonesia, Thailand, and Hong Kong, with IPO proceeds expected to partially support overseas expansion [7]. Group 4: Market Context and Future Outlook - The advancement of the IPO project signifies that Plant Doctor will soon address questions regarding its future value under the scrutiny of capital markets, providing a significant market reference for local brands focusing on niche segments and growing through physical entities [8]. - The capital market is increasingly cautious about consumer brand valuations, focusing on profitability certainty, sustainable growth, and model resilience, with Plant Doctor offering a new path distinct from traditional cosmetics companies through its clear single-brand store model and validated offline scale [9].